natgillin/translations-raw huggingface dataset:
A risk management plan has been developed to ensure that Odomzo is used as safely as possible. 
Pripremljen je plan upravljanja rizikom kako bi se osigurala što sigurnija primjena lijeka Odomzo.
Patients were started on two different doses of Odomzo: 200 or 800 mg once a day. 
Terapija bolesnika započeta je s dvije različite doze lijeka Odomzo: 200 ili 800 mg jednom na dan.
Odomzo is a cancer medicine used to treat adults with basal cell carcinoma (a type of skin cancer) which is locally advanced (has started to spread nearby) and which cannot be treated either by surgery or by radiotherapy (treatment with radiation). 
Odomzo je antitumorski lijek koji se koristi za liječenje odraslih osoba s karcinomom bazalnih stanica (tipom raka kože) koji je lokalno uznapredovao (počeo se širiti u okolno tkivo) i koji se ne može liječiti kirurškim zahvatom ili radioterapijom (terapijom zračenjem).
Odomzo is continued as long as it has a beneficial effect or until it can no longer be taken because of side effects. 
Terapija lijekom Odomzo nastavlja se tako dugo dok terapija ima korisno djelovanje ili se više ne može uzimati zbog nuspojava.
Why is Odomzo approved? 
Zašto je lijek Odomzo odobren?
It also considered that the side effects were manageable. 
Zaključio je da je nuspojave moguće kontrolirati.
Other information about Odomzo 
Ostale informacije o lijeku Odomzo
By attaching to this protein, sonidegib blocks the Hedgehog signalling pathway and thereby reduces the growth and spread of cancer cells. 
Vezivanjem na ovaj protein, sonidegib inhibira signalni put Hedgehog i time smanjuje rast i širenje stanica raka.
Odomzo was studied in one main study involving 230 patients with basal cell carcinoma which was either locally advanced or metastatic (spread to other parts of the body). 
Odomzo je ispitan u jednom glavnom ispitivanju koje je obuhvatilo 230 bolesnika s karcinomom bazalnih stanica koji je lokalno uznapredovao ili metastazirao (raširio se u druge dijelove tijela).
The Committee considered that the benefits of Odomzo had been shown for patients with locally advanced disease. 
Odbor je smatrao da su koristi lijeka Odomzo dokazane za bolesnike s lokalno uznapredovalom bolesti.
Women who are pregnant or who are breastfeeding must not take Odomzo. 
Trudnice ili dojilje ne smiju uzimati lijek Odomzo.
Some cancers, including basal cell carcinoma, result from overactivity of a specific set of cell processes called the Hedgehog signalling pathway. 
Pojedine vrste raka, uključujući karcinom bazalnih stanica, rezultat su prekomjerne aktivnosti određenog niza staničnih postupaka naziva signalni put Hedgehog.
Odomzo can only be obtained with a prescription. 
Odomzo se izdaje samo na liječnički recept.
Furthermore, the company is to supply further analysis from its main study on the effectiveness and safety of Odomzo, including its effectiveness in rapidly growing and slow-growing basal cell carcinoma. 
Nadalje, tvrtka treba dostaviti daljnju analizu glavnog ispitivanja o djelotvornosti i sigurnoj primjeni lijeka Odomzo, uključujući njegovu djelotvornost u slučaju brzorastućeg i spororastućeg karcinomu bazalnih stanica.
What are the risks associated with Odomzo? 
Koji su rizici povezani s lijekom Odomzo?
In addition, the company will send a letter to doctors when Odomzo is launched. 
Nadalje, tvrtka će dostaviti pismo liječenja kada se lijek Odomzo stavi u promet.
Odomzo contains the active substance sonidegib. 
Odomzo sadrži djelatnu tvar sonidegib.
Sonidegib, the active substance in Odomzo, attaches to a protein that controls the Hedgehog signalling pathway. 
Sonidegib, djelatna tvar lijeka Odomzo, vezuje se na protein koji kontrolira signalni put Hedgehog.
The full EPAR and risk management plan summary for Odomzo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports. 
Cjeloviti EPAR za lijek Odomzo kao i sažetak plana upravljanja rizikom za lijek Odomzo nalaze se na internetskim stranicama Agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports Više informacija o terapiji lijekom Odomzo pročitajte u uputi o lijeku (također dio EPAR-a) ili se obratite svojem liječniku ili ljekarniku.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Odomzo, including the precautions to be followed by healthcare professionals and patients. 
Na temelju tog plana, u sažetku opisa svojstava lijeka kao i u uputi o lijeku za lijek Odomzo nalaze se sigurnosne informacije, uključujući odgovarajuće mjere opreza kojih se zdravstveni djelatnici i bolesnici trebaju pridržavati.
Response rates were less than 20% in patients with metastatic cancer started on either 200 or 800 mg Odomzo and the company withdrew its application for use in metastatic basal cell carcinoma. 
Stopa odgovora bila je manja od 20 % u bolesnika kod kojih je rak metastazirao, čija je terapija započela s dozom od 200 ili 800 mg lijeka Odomzo te je društvo povuklo svoj zahtjev za primjenu u slučaju metastaziralog karcinoma bazalnih stanica.
It is not intended to provide practical advice on how to use Odomzo. 
Svrha sažetka nije davati praktične savjete o primjeni lijeka Odomzo.
For practical information about using Odomzo, patients should read the package leaflet or contact their doctor or pharmacist. 
Praktične informacije o primjeni lijeka Odomzo pročitajte u uputi o lijeku, odnosno obratite se svojem liječniku ili ljekarniku.
What benefits of Odomzo have been shown in studies? 
Koje su koristi lijeka Odomzo utvrđene u ispitivanjima?
Therefore, women taking Odomzo must take effective measures to prevent pregnancy during treatment and for 20 months after stopping it. Men taking Odomzo must always use condoms for sex with female partners and for 6 months after stopping treatment. 
Stoga, žene koje uzimaju lijek Odomzo moraju poduzeti djelotvorne mjere kako bi spriječile trudnoću tijekom terapije i tijekom 20 mjeseci nakon prestanka uzimanja terapije.
How is Odomzo used? 
Kako se Odomzo koristi?
How does Odomzo work? 
Kako djeluje Odomzo?
Women who could potentially become pregnant must not take Odomzo unless they comply with the Odomzo pregnancy prevention programme. 
Žene reproduktivne dobi smiju uzimati lijek Odomzo jedino ako usklade terapiju lijeka Odomzo sa svojim rasporedom prevencije trudnoće.
It should only be prescribed by a specialist doctor experienced in the treatment of advanced basal cell carcinoma or under the supervision of such a doctor. 
Lijek smije propisati, odnosno njegovo propisivanje smije nadzirati, samo liječnik specijalist s iskustvom u terapiji uznapredovalog karcinoma bazalnih stanica.
For the full list of all side effects reported with Odomzo, see the package leaflet. 
Potpuni popis svih nuspojava zabilježenih pri primjeni lijeka Odomzo potražite u uputi o lijeku.
Cats and dogs 
Za mačke i pse
Solution for injection 
Otopina za injekcije
Subcutaneos use 
Primjena supkutano
1 vial 
1 Staklena bočica
1 bottle + 1 oral syringe + 1 press-in bottle adapter 
1 boca +1 oralna štrcaljka za usta + 1 nastavak za bocu
1 vial + 1 vial + 2 vial adapters + 1 syringe + 1 infusion set + 2 alcohol swabs +1 sterile swab + 1 plaster 
1 bočica + 1 bočica + 2 nastavka za bočice + 1 štrcaljka + 1 set za infuziju s iglom+ 2 alkoholna jastučića +1 sterilni netkani jastučić + 1 ljepljivi flaster
Powder: 2100 U Solvent: 20 ml 
Prašak : 2100 U Otapalo: 20 ml
2100 U Powder for solution for injection 
2100 U prašak i otapalo za otopinu za injekciju
Intravenous use Powder: vial (glass) 
Prašak: bočica (staklo) Otapalo: bočica (staklo)
The amount of Icandra that people have to take varies depending on their condition. 
Količina Icandre koju ljudi moraju uzimati ovisi o njihovu stanju.
Icandra with alcohol 
Icandra s alkoholom
If you take more Icandra than you should 
Ako uzmete više Icandre nego što ste trebali
Other medicines and Icandra 
Drugi lijekovi i Icandra
Your doctor will discuss with you the potential risk of taking Icandra during pregnancy. 
Vaš liječnik će s Vama razgovarati o mogućim rizicima uzimanja Icandre tijekom trudnoće.
What Icandra is and what it is used for 
Što je Icandra i za što se koristi
Icandra is not a substitute for insulin. 
Icandra nije zamjena za inzulin.
When and how to take Icandra - Swallow the tablets whole with a glass of water, - Take one tablet in the morning and the other in the evening with or just after food. 
Kada i kako uzimati Icandru - Tablete progutajte cijele sa čašom vode, - Uzmite jednu tabletu ujutro i drugu navečer s obrokom ili odmah nakon obroka.
Do not stop taking Icandra unless your doctor tells you to. 
Nemojte prestati uzimati Icandru ako Vam to nije rekao Vaš liječnik.
If you take too many Icandra tablets, or if someone else takes your tablets, talk to a doctor or pharmacist immediately. 
Ako uzmete previše tableta Icandre, ili ako je netko drugi uzeo Vaše tablete, odmah se obratite liječniku ili ljekarniku.
Do not take Icandra - if you are allergic to vildagliptin, metformin or any of the other ingredients of this medicine (listed in section 6). 
Nemojte uzimati Icandru - ako ste alergični na vildagliptin, metformin ili neki drugi sastojak ovog lijeka (naveden u dijelu 6).
PA/Alu/PVC/Alu 2 years PCTFE/PVC/Alu 18 months 
PA/Alu/PVC/Al 2 godine PCTFE/PVC/Al 18 mjeseci
Icandra should not be used during pregnancy. 
Icandra se ne smije primjenjivati tijekom trudnoće.
- Do not use Icandra if you are pregnant or breast-feeding (see also “Do not take Icandra”). 
- Nemojte uzimati Icandru ako ste trudni ili dojite (također pogledajte „Nemojte uzimati Icandru“).
During treatment with Icandra, your doctor will check your kidney function at least once a year or more frequently if you are elderly and/or have worsening renal function. 
Tijekom liječenja lijekom Icandra, liječnik će Vam provjeravati funkciju bubrega najmanje jedanput godišnje ili češće ako ste starija osoba i/ili ako Vam se funkcija bubrega pogoršava.
If pancreatitis is suspected, vildagliptin should be discontinued; if acute pancreatitis is confirmed, vildagliptin should not be restarted. 
Ako postoji sumnja na pankreatitis, treba prestati uzimati vildagliptin; ako je akutni pankreatitis potvrđen, vildagliptin se ne smije ponovo uzimati.
You are also advised to pay particular attention to new onset of blisters or ulcers while taking Icandra. 
Također Vam se savjetuje da posvetite posebnu pozornost novoj pojavi mjehurića ili čireva dok uzimate Icandru.
Your doctor will tell you exactly the dose of Icandra to take. 
Liječnik će Vam reći točno koliko tableta Icandre trebate uzimati.
If no adequate strength of Icandra is available, individual monocomponents should be used instead of the fixed dose combination. 
Ako nije dostupna odgovarajuća jačina lijeka Icandra, potrebno je primijeniti pojedinačne komponente zasebno umjesto fiksne kombinacije.
If you need to have an injection of a contrast medium that contains iodine into your bloodstream, for example in the context of an X-ray or scan, you must stop taking Eucreas before or at the time of the injection. 
Ako trebate dobiti injekciju kontrastnog sredstva koje sadrži jod u krvnu žilu, na primjer, u sklopu rendgenskog snimanja ili skeniranja, morate prestati uzimati lijek Icandra prije ili u vrijeme injekcije.
What Icandra is and what it is used for What you need to know before you take Icandra How to take Icandra 
Što je Icandra i za što se koristi Što morate znati prije nego počnete uzimati Icandru Kako uzimati Icandru
Food does not affect the extent and rate of absorption of vildagliptin from Icandra. 
Hrana ne utječe na opseg i brzinu apsorpcije vildagliptina iz Icandre.
Ketoacidosis is a condition in which substances called ketone bodies accumulate in the blood and which can lead to diabetic pre-coma. 
Ketoacidoza je stanje u kojem se tvari koje se nazivaju ketonska tijela nakupljaju u krvi i mogu dovesti do dijabetičke predkome.
Icandra may cause a very rare, but very serious side effect called lactic acidosis, particularly if your kidneys are not working properly. 
Icandra može uzrokovati vrlo rijetku, ali vrlo ozbiljnu nuspojavu koja se naziva laktacidoza, osobito ako Vam bubrezi ne rade ispravno.
Avoid excessive alcohol intake while taking Icandra since this may increase the risk of lactic acidosis (please see section “Warnings and precautions”). 
Izbjegavajte prekomjerni unos alkohola dok uzimate Icandru jer to može povećati rizik od laktacidoze (vidjeti dio „Upozorenja i mjere opreza”).
You may need more frequent blood glucose and kidney function tests or your doctor may need to adjust the dosage of Icandra. 
Možda ćete češće morati raditi pretrage glukoze u krvi ili testove funkcije bubrega ili će Vam liječnik trebati prilagoditi dozu lijeka Icandra.
Icandra is not a substitute for insulin in insulin-requiring patients and should not be used in patients with type 1 diabetes. 
Icandra nije zamjena za inzulin u bolesnika koji trebaju inzulin i ne smije se primjenjivati u bolesnika sa šećernom bolešću tipa 1.
Information regarding overdose with vildagliptin is limited. 
Vildagliptin Informacije o predoziranju vildagliptinom su ograničene.
If you need to have major surgery you must stop taking Icandra during and for some time after the procedure. 
Ako se morate podvrgnuti velikom kirurškom zahvatu, morate prestati uzimati lijek Icandra tijekom i još neko vrijeme nakon zahvata.
What Icandra contains - The active substances are vildagliptin and metformin hydrochloride. 
Što Icandra sadrži - Djelatne tvari su vildagliptin i metforminklorid.
Your doctor will decide when you must stop and when to restart your treatment with Icandra. 
Liječnik će odlučiti kada morate prekinuti i kada ćete nastaviti s liječenjem lijekom Icandra.
Icandra is not recommended for use in children and adolescents (< 18 years). 
Icandra se ne preporučuje za primjenu u djece i adolescenata (<18 godina).
There have been no therapeutic clinical trials conducted with Icandra. 
Nisu provedena terapijska klinička ispitivanja s Icandrom.
The following statements reflect the pharmacokinetic properties of the individual active substances of Icandra. 
Izjave u nastavku odražavaju farmakokinetička svojstva pojedinih djelatnih tvari u Icandri.
The safety and efficacy of Icandra in children and adolescents (< 18 years) have not been established. 
Sigurnost i djelotvornost Icandre u djece i adolescenata (<18 godina) nisu ustanovljene.
This type of diabetes is also known as noninsulin-dependent diabetes mellitus. 
Ovaj tip šećerne bolesti je također poznat kao dijabetes melitus neovisan o inzulinu.
Lactic acidosis, a very rare but serious metabolic complication, most often occurs at acute worsening of renal function, or cardiorespiratory illness or sepsis. 
Laktacidoza, vrlo rijetka, ali ozbiljna metabolička komplikacija, najčešće nastaje pri akutnom pogoršanju funkcije bubrega ili kardiorespiratornoj bolesti ili sepsi.
Stop taking Icandra for a short time if you have a condition that may be associated with dehydration (significant loss of body fluids) such as severe vomiting, diarrhoea, fever, exposure to heat or if you drink less fluid than normal. 
Prestanite nakratko uzimati Icandru ako imate stanje koje može biti povezano s dehidracijom (značajan gubitak tjelesnih tekućina) kao što je jako povraćanje, proljev, vrućica, izloženost toplini ili ako pijete manje tekućine nego obično.
What you need to know before you take Icandra 
Što morate znati prije nego počnete uzimati Icandru
How Icandra works 
Kako Icandra djeluje
Some patients have had the following side effects while taking Icandra and insulin: 
Neki su bolesnici imali sljedeće nuspojave kada su uzimali Icandru i inzulin:
The active substances of Icandra, vildagliptin and metformin, belong to a group of medicines called “oral antidiabetics”. 
Djelatne tvari Icandre, vildagliptin i metformin pripadaju skupini lijekova koji se nazivaju „oralni antidijabetici”.
Taking Icandra with or just after food may reduce gastrointestinal symptoms associated with metformin (see also section 5.2). 
Uzimanje Icandre uz obrok ili neposredno nakon njega može ublažiti gastrointestinalne simptome povezane s metforminom (vidjeti dio 5.2).
• Lactic acidosis (very rare: may affect up to 1 user in 10,000): Icandra may cause a very rare, but very serious side effect called lactic acidosis (see section “Warnings and precautions”). 
• Laktacidoza (vrlo rijetko: može se javiti u manje od 1 na 10 000 osoba): Icandra može uzrokovati vrlo rijetku, ali vrlo ozbiljnu nuspojavu koja se naziva laktacidoza (vidjeti dio “Upozorenja i mjere opreza”).
No studies on the effect on human fertility have been conducted for Icandra (see section 5.3). 
Nisu provedena nikakva ispitivanja o učinku Icandre na plodnost u ljudi (vidjeti dio 5.3).
Adults with normal renal function (GFR ≥ 90 ml/min) The dose of antihyperglycaemic therapy with Icandra should be individualised on the basis of the patient's current regimen, effectiveness and tolerability while not exceeding the maximum recommended daily dose of 100 mg vildagliptin. 
Odrasli s normalnom funkcijom bubrega (GFR≥90 ml/min) Doza antihiperglikemijske terapije Icandrom mora biti individualizirana prema bolesnikovom postojećem režimu, učinkovitosti i podnošljivosti, ne prelazeći pritom najvišu preporučenu dnevnu dozu od 100 mg vildagliptina.
However, bioequivalence of Icandra with co-administered vildagliptin and metformin has been demonstrated (see section 5.2). 
Međutim, bioekvivalencija Icandre s istodobno primijenjenim vildagliptinom i metforminom je dokazana (vidjeti dio 5.2).
As metformin is excreted via the kidney, and elderly patients have a tendency to decreased renal function, elderly patients taking Icandra should have their renal function monitored regularly (see sections 4.4 and 5.2). 
Budući da se metformin izlučuje putem bubrega, a stariji bolesnici imaju sklonost smanjenju bubrežne funkcije, u starijih bolesnika koji primaju Icandru treba redovito pratiti funkciju bubrega (vidjeti dijelove 4.4 i 5.2).
The rate and extent of absorption of metformin from Icandra 50 mg/1000 mg were decreased when given with food as reflected by the decrease in Cmax by 26%, AUC by 7% and delayed Tmax (2.0 to 4.0 h). 
Brzina i opseg apsorpcije metformina iz Icandre 50 mg/1000 mg se smanjuju kada se daje s hranom što se odražava sniženjem Cmax za 26%, AUC za 7% i odgođenim Tmax (2,0 do 4,0 h).
Due to both the potential risk of neonate hypoglycaemia related to metformin and the lack of human data with vildagliptin, Icandra should not be used during breast-feeding (see section 4.3). 
Zbog mogućeg rizika za hipoglikemiju u novorođenčeta vezanu uz metformin kao i zbog nedovoljno podataka u ljudi vezanih za vildagliptin, Icandra se ne smije primjenjivati tijekom dojenja (vidjeti dio 4.3).
If you have reduced kidney function, your doctor may prescribe a lower dose. 
Ako imate smanjenu funkciju s bubrega, liječnik Vam može propisati nižu dozu.
Metformin is contraindicated in patients with GFR < 30 ml/min and should be temporarily discontinued in the presence of conditions that alter renal function (see section 4.3). 
Metformin je kontraindiciran u bolesnika s GFR<30 ml/min i njegovu je primjenu potrebno privremeno prekinuti ako su prisutna stanja koja mijenjaju funkciju bubrega, (vidjeti dio 4.3).
Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue Icandra. 
U bolesnika koji razviju žuticu ili druge znakove koji upućuju na poremećaj jetrene funkcije treba prekinuti liječenje Icandrom.
You should stop taking Icandra and see your doctor immediately if you experience the following side effects: 
Prestanite uzimati Icandru i odmah otiđite svom liječniku ako osjetite sljedeće nuspojave:
Talk to your doctor, pharmacist or nurse before taking Icandra if you are taking an anti-diabetic medicine known as a sulphonylurea. 
Obratite se svom liječniku, ljekarniku ili medicinskoj sestri prije nego uzmete Icandru ako uzimate antidijabetički lijek iz skupine sulfonilureja.
Following withdrawal of treatment with Icandra and LFT normalisation, treatment with Icandra should not be re-initiated. 
Nakon prekida liječenja sa Icandrom i normalizacije testova jetrene funkcije, liječenje sa Icandrom se ne smije ponovno započeti.
Stop taking Icandra and contact a doctor or the nearest hospital immediately if you experience some of the symptoms of lactic acidosis, as this condition may lead to coma. 
Prestanite uzimati Icandru i odmah se obratite liječniku ili otiđite u najbližu bolnicu ako osjetite neke od simptoma laktacidoze, jer to stanje može dovesti do kome.
Should an increase in AST or in ALT of 3x ULN or greater persist, withdrawal of Icandra therapy is recommended. 
Potraju li povišene vrijednosti AST-a ili ALT-a na razini od 3x GGN ili većoj, preporučuje se prekinuti terapiju Icandrom.
If this happens you must stop taking Icandra and contact a doctor or the nearest hospital immediately, as lactic acidosis may lead to coma. 
Ako Vam se to dogodi, morate prestati uzimati Lijek Icandra i odmah se obratiti liječniku ili otići u najbližu bolnicu, jer laktacidoza može dovesti do kome.
There are no adequate data from the use of Icandra in pregnant women. 
Nema odgovarajućih podataka o primjeni Icandre u trudnica.
Some patients have experienced the following side effects while taking Icandra and a sulphonylurea: • Common: dizziness, tremor, weakness, low blood glucose, excessive sweating. 
Neki su bolesnici imali sljedeće nuspojave kada su uzimali Icandru i sulfonilureju: • često: omaglica, tremor, slabost, niska razina glukoze u krvi, pojačano znojenje.
• Inflammation of the pancreas (pancreatitis) (frequency not known): Symptoms include severe and persistent pain in the abdomen (stomach area), which might reach through to your back as well as nausea and vomiting. 
• Upala gušterače (pankreatitis) (učestalost nepoznata): simptomi uključuju jaku i upornu bol u trbuhu (područje trbuha), koja bi se mogla proširiti do leđa te mučninu i povraćanje.
When Icandra is used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia. 
Kad se Icandra primjenjuje u kombinaciji sa sulfonilurejom, može se razmotriti niža doza sulfonilureje kako bi se smanjio rizik od hipoglikemije.
There have been no formal interaction studies for Icandra. 
Nisu provedena formalna ispitivanja interakcija za Icandru.
Icandra should not be used in patients with hepatic impairment, including those with pre-treatment alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times the upper limit of normal (ULN) (see sections 4.3, 4.4 and 4.8). 
Icandra se ne smije primjenjivati u bolesnika s oštećenjem jetre, uključujući u kojih su vrijednosti alanin aminotransferaze (ALT) ili aspartat aminotransferaze (AST) prije početka liječenja bile >3 vrijednosti gornje granice normale (GGN) (vidjeti dijelove 4.3, 4.4 i 4.8).
If you stop taking Icandra 
Ako prestanete uzimati Icandru
- For patients switching from co-administration of vildagliptin and metformin as separate tablets: Icandra should be initiated at the dose of vildagliptin and metformin already being taken. 
U bolesnika koji prelaze s istodobne primjene vildagliptina i metformina kao zasebnih tableta: Icandru je potrebno započeti u dosadašnjim dozama vildagliptina i metformina.
If you forget to take Icandra 
Ako ste zaboravili uzeti Icandru
Children and adolescents The use of Icandra in children and adolescents up to 18 years of age is not recommended. 
Djeca i adolescenti Icandra se ne preporučuje za primjenu u djece i adolescenata ispod 18 godina.
The recommended dose is one film-coated tablet of either 50 mg/850 mg or 50 mg/1000 mg taken twice a day. 
Preporučena doza je jedna filmom obložena tableta od 50 mg/850 mg ili 50 mg/1000 mg koja se uzima dvaput na dan.
Liver function should be monitored during treatment with Icandra at three-month intervals during the first year and periodically thereafter. 
Jetrenu funkciju treba pratiti tijekom liječenja Icandrom u razmacima od tri mjeseca tijekom prve godine liječenja te povremeno nakon toga.